A Study of the Drugs Talazoparib and Temozolomide in Prostate Cancer
Status:
Recruiting
Trial end date:
2023-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine what the safest dose of talazoparib plus
temozolomide for participants with metastatic castration resistant prostate cancer.